B+
Bull case
20%
Probability
Target price
$5.19
-80.4% vs current
AGIO
AgiosFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$4.08
-84.6% vs current
B-
Bear case
30%
Probability
Target price
$2.60
-90.2% vs current
AI sentiment snapshot
Latest data as of 2025-10-10
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market sentiment is cautious and event-driven: low absolute price levels keep institutional interest limited and amplify moves on clinical, BD, or financing news [#RankAlpha][#EDGAR]. Short-term tone hinges on cash/runway updates and upcoming results.
RankAlpha Sentiment AI - 2025-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly earnings / guidance updateHigh impact
Quarterly results and management commentary that can change cash-runway expectations and near-term guidance; historically a volatility driver [#EDGAR][#RankAlpha].
-catalystClinical readouts (hematology / rare disease)High impact
Mid-/late-stage efficacy or safety data for core programs — binary outcomes that materially re-rate valuation if positive or negative [#EDGAR].
-catalystBusiness development / partneringHigh impact
Licensing or co-development deals that extend runway or de-risk assets; timing and scale uncertain [#PR].
Recommendation
N/A
No formal recommendation provided.
As of 2025-10-10 • Updated nightlySource: Internal modelMethodology